Price T Rowe Associates Inc. MD increased its holdings in STAAR Surgical (NASDAQ:STAA – Free Report) by 6.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The company owned 30,310 shares of the medical equipment supplier after purchasing an additional 1,813 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.06% of STAAR Surgical worth $1,161,000, according to its most recent SEC filing.

Other major investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of STAAR Surgical by 8.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,679 shares of the medical instrument supplier’s stock worth $708,000 after buying an additional 1,821 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of STAAR Surgical by 64.3% in the 4th quarter. Mutual of America Capital Management LLC now owns 56,260 shares of the medical instrument supplier’s stock worth $1,756,000 after buying an additional 22,021 shares during the same period. Perigon Wealth Management LLC increased its holdings in shares of STAAR Surgical by 10.7% in the 4th quarter. Perigon Wealth Management LLC now owns 7,288 shares of the medical equipment supplier’s stock worth $227,000 after purchasing an additional 703 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of STAAR Surgical in the 4th quarter valued at about $762,000. Finally, Handelsbanken Fonder AB increased its stake in STAAR Surgical by 18.0% in the 4th quarter. Handelsbanken Fonder AB now owns 10,500 shares of the medical equipment supplier’s stock worth $328,000 after purchasing an additional 1,600 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

Analysts set new price targets

Several research analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday. Mizuho increased their price target on shares of STAAR Surgical from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Piper Sandler increased their price target on STAAR Surgical from $33.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, May 8th. Canaccord Genuity Group decreased their price target on STAAR Surgical from $43.00 to $41.00 and gave the company a “hold” rating in a research note on Thursday. Finally, Morgan Stanley downgraded STAAR Surgical from “equal weight” to “underweight” and decreased their price target for the company from $50.00 to $37.00 in a research report on Monday, July 15. One research analyst rated the stock with a “sell” rating, five gave a “hold” rating and five gave a “buy” rating. According to MarketBeat, the stock has an average rating of “hold” and an average price target of $47.75.

Check out our latest report on STAA

STAAR Surgical shares down 4.9%

STAAR Surgical shares opened at $38.38 on Friday. The stock has a market cap of $1.89 billion, a P/E ratio of 123.81, and a beta of 0.59. STAAR Surgical has a 12-month low of $26.66 and a 12-month high of $52.68. The company’s 50-day moving average is $41.94 and its 200-day moving average is $39.89.

STAAR Surgical (NASDAQ:STAA – Get Free Report) released its latest earnings results on Wednesday, August 7. The medical instruments provider reported earnings per share of $0.15 for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $95.22 million. STAAR Surgical had a return on equity of 6.83% and a net margin of 4.69%. STAAR Surgical’s quarterly revenue grew 7.3% year over year. In the same quarter last year, the company reported earnings per share of $0.23. On average, sell-side analysts expect STAAR Surgical to report earnings per share of $0.08 for the current year.

About STAAR Surgical

(Free report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets and sells implantable ocular lenses and associated systems for delivering the lenses to the eye. The company offers implantable collamer lenses (ICLs) to treat vision disorders such as myopia, hyperopia, astigmatism and presbyopia.

Selected articles

Want to see which other hedge funds hold STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA – Free Report).

Get daily news and reviews for STAAR Surgical – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.